Recent

% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • thom988 thom988 Oct 24, 2013 10:59 AM Flag

    Burnaka... do you have any concerns regarding the volume of insider selling...

     

    versus the volume of insider buying?

    Thanks in advance

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • burnaka@sbcglobal.net burnaka Oct 24, 2013 1:10 PM Flag

      No because the insiders own little anyway. The other reason is the company has an incentive based options program with the average price of 4.67 per option. There are roughly 25 million shares in the option program which if eventually exercised would give insiders and employees near 20% ownership. It is an incentive based plan which beats JUST handing out free candy, and at 4.67 they are not dirt cheap options. Plus it was a FUND that owned a major stake over 10% selling. Two of those listed as insiders Liam Radcliffe and Mark Lampert both run small biotech funds. Lampert has sold none that I can find. Not every stock is like OPk where insiders own 50%, lol.

      Buyoutmoney might be on the right track. I looked at AztraZenica pipeline phase 3 today. There are I think 8, of those 5 are partnered, three partners are big, Amgen etc., the two small companies they partnered with, they bought them out to grow a depleted phase 3 pipeline and get all other research.

      Buying Arry for 3x cap is stealing if 1/2 their phase 3 ever go to market. I see arry as a buyout target because of the almost 3 billion royalty packages, of course NO DRUG might ever get approved, but like I said before, their partners are heavy weights, they WOULD not go PHASE 3 without a very solid phase 2.

      I am hoping for a 1.00 pull back that likely never comes, and will be the first to whine if AstraZenica comes in offering 15-18 bucks. So I am being penny wise, with a toe nail in the water, lol.

      • 2 Replies to burnaka
      • No because the insiders own little anyway. The other reason is the company has an incentive based options program with the average price of 4.67 per option. There are roughly 25 million shares in the option program which if eventually exercised would give insiders and employees near 20% ownership. It is an incentive based plan which beats JUST handing out free candy, and at 4.67 they are not dirt cheap options. Plus it was a FUND that owned a major stake over 10% selling. Two of those listed as insiders Liam Radcliffe and Mark Lampert both run small biotech funds. Lampert has sold none that I can find. Not every stock is like OPk where insiders own 50%, lol.

      • The insiders own 6% directly, but have the potential to own 26% if they sell no more shares. The sales are small in relation to potential share ownership. Just throwing this out there, so yah they sold about 21 million dollars worth by 3 insiders over two years, and most by a fund manager likely looking to buy other items, Radcliffe = almost all sales. Shares sold 24 months = 3,490,510 - 3,140,070 ( Radcliffe ) all other sales = 350,440 shares by two people.

    • yes it was only 1 member selling, bullish to me I really think arry will be bought out within the next 2 months . Just look at their pipeline, would be cheaper than paying all these milestone payments.

 
ARRY
7.19-0.120(-1.64%)Apr 24 4:00 PMEDT